KR890001533A - 레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용 - Google Patents

레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용 Download PDF

Info

Publication number
KR890001533A
KR890001533A KR1019870007874A KR870007874A KR890001533A KR 890001533 A KR890001533 A KR 890001533A KR 1019870007874 A KR1019870007874 A KR 1019870007874A KR 870007874 A KR870007874 A KR 870007874A KR 890001533 A KR890001533 A KR 890001533A
Authority
KR
South Korea
Prior art keywords
composition
active ingredient
ldme
mixed
levodopa methyl
Prior art date
Application number
KR1019870007874A
Other languages
English (en)
Other versions
KR950002150B1 (ko
Inventor
키에시 파올로
Original Assignee
원본미기재
키에시 파프마세우티시 에스·피·에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT20737/86A external-priority patent/IT1190342B/it
Priority claimed from IT19221/87A external-priority patent/IT1203321B/it
Application filed by 원본미기재, 키에시 파프마세우티시 에스·피·에이 filed Critical 원본미기재
Publication of KR890001533A publication Critical patent/KR890001533A/ko
Application granted granted Critical
Publication of KR950002150B1 publication Critical patent/KR950002150B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 유효 성분으로서 레보도파 메틸 에스테르(LDME) 및 제약 담체 또는 희석제를 함유하는 제약 조성물.
  2. 제1항에 있어서,도파민 동근군, 콜린작용 억제제, 항우울증제, 말초 디카르복실라제 억제제, MAD-B억제제 또는 이들의 혼합물로부터 선택되는 다른 유효 효소와 함께 LDME를 함유하는 조성물.
  3. 제1항 내지 제2항에 있어서, 유효 성분으로서 LDME만을 함유하거나 또는 액상 담체 또는 희석제를 혼합시킨 용액 조성물.
  4. 제1항 내지 제2항에 있어서, 유효 성분으로서 LDME만을 함유하거나 또는 액상 담체 또는 희석제를 혼합시킨 고상 형태의 조성물.
  5. 제1항 내지 제4항에 있어서, 경구, 협측, 설하, 직장, 비경구, 임의의 주입직 시스템을 사용하여 피하 또는 복강내 경로로 투입되는 조성물.
  6. 전항중 어느 하나의 항에 있어서, 고상 형태일 경우, 단위 투여량 당 유효 성분을 100 내지 1.000mg 함유하거나, 또는 액상 형태일 경우, 유효소를 50 내지 400mg/ml 함유하는 조성물.
  7. 제2항 내지 제4항에 있어서, 단위 투여량 당 레보도파 메틸 에스테르를 100 내지 30mg 함유하고, 벤세라지드 또는 카르비도파 또는 데프레닐이 각각 2:1 내지 5:1, 4:1 내지 20:1, 20:1, 20:1 내지 100:1 의 비율로 혼합되거나 또는 이들의 혼합물과 혼합시킨 조성물.
  8. 제2항 내지 제3항에 있어서, 레보도파 메틸 에스테르를 50 내지 40mg/ml 함유하고, 벤세라지드 또는 카르비도파 또는 데프레닐이 각각 2:1 내지 10:1, 4:1 내지 20:1, 20:1, 20:1 내지 100:1 의 비율로 혼합되거나 또는 이들의 혼합물과 혼합시킨 조성물.
  9. 전항 중 어느 하나의 항에 있어서, 유효 성분이 연장된 방식 또는 축차(逐次) 방색으로 방출되는 것을 특징으로 하는 조성물.
  10. 전항 중 어느 하나의 항에 있어서, 위장 조직을 바이패스하도록 투여되는 조성물.
  11. 피킨슨병 및 관련된 신경학적 증후군 치료에 유용한 의약품 제조를 위한 LDME의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870007874A 1986-06-10 1987-07-21 레보도파 메틸에스테르를 함유하는 제약 조성물 KR950002150B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT20737A/86 1986-06-10
IT20737/86A IT1190342B (it) 1986-06-10 1986-06-10 Composizioni farmaceutiche contenenti levodopa metil estere,loro procedimento di preparazione e relative applicazioni terapeutiche
IT19221A/87 1987-01-30
IT19221/87A IT1203321B (it) 1987-01-30 1987-01-30 Composizioni farmaceutiche contenenti levodora metil estere,loro prodecimento di preparazione e relative applicazioni terapeutiche

Publications (2)

Publication Number Publication Date
KR890001533A true KR890001533A (ko) 1989-03-27
KR950002150B1 KR950002150B1 (ko) 1995-03-14

Family

ID=26327098

Family Applications (2)

Application Number Title Priority Date Filing Date
KR870005806A KR880000092A (ko) 1986-06-10 1987-06-09 레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용
KR1019870007874A KR950002150B1 (ko) 1986-06-10 1987-07-21 레보도파 메틸에스테르를 함유하는 제약 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR870005806A KR880000092A (ko) 1986-06-10 1987-06-09 레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용

Country Status (13)

Country Link
US (2) US4826875A (ko)
EP (1) EP0252290B1 (ko)
JP (1) JP2572768B2 (ko)
KR (2) KR880000092A (ko)
AT (1) ATE76747T1 (ko)
AU (1) AU605154B2 (ko)
CA (1) CA1303509C (ko)
DE (2) DE3779500T2 (ko)
ES (1) ES2042520T3 (ko)
GR (1) GR880300058T1 (ko)
HU (1) HUT43952A (ko)
NZ (1) NZ220631A (ko)
PT (1) PT85055B (ko)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
DE4325435A1 (de) * 1993-07-29 1995-02-02 Basf Ag Neue Wirkstoffkombination
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
WO1996026720A1 (en) * 1995-03-02 1996-09-06 R.P. Scherer Limited Pharmaceutical compositions comprising monoamine oxidase b inhibitors
US20050106241A1 (en) * 1995-02-03 2005-05-19 Brewer Francesca M. Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors
AU718096C (en) 1995-06-07 2001-11-22 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
CN1207675A (zh) * 1995-11-06 1999-02-10 萨默塞特药品有限公司 丙炔***的经颊和舌下给药法
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
ES2241064T3 (es) 1996-12-18 2005-10-16 Teva Pharmaceutical Industries, Ltd. Derivados de aminoindano.
US20040151768A1 (en) * 1997-07-23 2004-08-05 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
ES2178405T3 (es) 1998-03-16 2002-12-16 Somerset Pharmaceuticals Inc Uso de selegilina o de desmetilselegilina para tratar heridas, quemaduras y lesiones cutaneas.
WO2000027385A1 (en) 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd., Et Al. Dispersible compositions containing l-dopa ethyl ester
NZ512030A (en) 1998-11-10 2003-10-31 Teva Pharma Process for manufacture of L-dopa ethyl ester
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
US6737547B1 (en) 1998-12-31 2004-05-18 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using N-acyl-1H-aminoindenes
US20020151526A1 (en) * 2000-10-06 2002-10-17 Gallop Mark A. Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
WO2004052841A1 (en) 2002-12-06 2004-06-24 Xenoport, Inc. Carbidopa prodrugs and uses thereof
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2004096141A2 (en) * 2003-04-25 2004-11-11 Indevus Pharmaceuticals, Inc. Method for promoting uninterrupted sleep by administration of trospium chloride
JP5160786B2 (ja) * 2003-08-29 2013-03-13 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
EA200600626A1 (ru) * 2003-10-20 2007-02-27 Тева Фармасьютикал Индастриес Лтд. Композиция и лекарственная форма продолжительного выделения леводопы
US7576073B2 (en) * 2004-05-28 2009-08-18 UNIVERSITé LAVAL Combined therapy for the treatment of parkinson's disease
AU2005252220B2 (en) * 2004-06-04 2011-06-02 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
US20060173074A1 (en) 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
US20080300204A1 (en) * 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
ZA200805511B (en) * 2005-12-05 2010-02-24 Xenoport Inc Levodopa prodrug mesylate, compositions thereof, and uses thereof
ES2632638T3 (es) * 2005-12-09 2017-09-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigilo de baja dosis para el tratamiento de la deficiencia cognitiva
BRPI0708071A8 (pt) * 2006-02-17 2017-12-26 Birds Pharma Gmbh Berolina Innovative Res & Development Services Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008076458A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
TW200843731A (en) * 2006-12-21 2008-11-16 Xenoport Inc Catechol protected levodopa diester prodrugs, compositions, and methods of use
EP2063867A2 (en) * 2006-12-22 2009-06-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
CN101677973A (zh) 2007-02-06 2010-03-24 奥里金生物医学股份有限公司 用于抑制神经传导的包括萜烯化合物的组合物以及方法
US20090143388A1 (en) * 2007-08-29 2009-06-04 Mohanakumar Kochupurackal Para Treatment of brain disorders
CN101283965B (zh) * 2007-10-26 2010-06-16 南京长澳医药科技有限公司 一种含左旋多巴甲酯的制剂及制备方法
NZ586870A (en) 2007-12-28 2012-10-26 Impax Laboratories Inc Controlled release formulations of levodopa, carbidopa andd a caboxylic acid
JP2011530543A (ja) 2008-08-13 2011-12-22 ニューロクエスト インク 感覚欠損を治療するための組成物および方法
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010047775A2 (en) * 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8286311B2 (en) 2008-10-31 2012-10-16 Jisook Paik Buckle
US20120128654A1 (en) * 2009-04-23 2012-05-24 University Of Cincinnati Allantoin Administration for the Treatment of Neurodegenerative Disease and Neurotrauma
EP3192500B1 (en) * 2009-05-19 2020-12-02 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
RU2537137C2 (ru) 2009-11-09 2014-12-27 Ксенопорт, Инк. Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
CN103442693A (zh) 2010-11-15 2013-12-11 纽罗德姆有限公司 L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用
WO2012079072A2 (en) * 2010-12-10 2012-06-14 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
BR112014030265A2 (pt) 2012-06-05 2017-06-27 Neuroderm Ltd composição farmacêutica líquida ou semissólida e método para tratar uma doença ou distúrbio neurológico ou de movimento.
EP2968371A4 (en) 2013-03-12 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Modulation of cellular dna repair activity to intercept malignancy
WO2014144037A1 (en) 2013-03-15 2014-09-18 Bristol-Myers Squibb Company Lxr modulators
CN105188380B (zh) 2013-03-15 2017-08-15 百时美施贵宝公司 Lxr调节剂
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
JP6506271B2 (ja) 2013-10-07 2019-04-24 インパックス ラボラトリーズ、 インコーポレイテッドＩｍｐａｘ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
FI3777833T3 (fi) 2014-03-13 2024-01-03 Neuroderm Ltd Dopa-dekarboksylaasin estäjän koostumuksia
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
EP3758754A1 (en) 2018-03-02 2021-01-06 Chiesi Farmaceutici S.p.A. A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3787581A (en) 1970-03-24 1974-01-22 M Sandler Pharmaceutical compositions and methods of treatment
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa

Also Published As

Publication number Publication date
DE252290T1 (de) 1988-06-09
ATE76747T1 (de) 1992-06-15
PT85055B (pt) 1994-10-31
NZ220631A (en) 1990-12-21
JPS6327428A (ja) 1988-02-05
EP0252290A2 (en) 1988-01-13
DE3779500T2 (de) 1993-01-21
US5017607A (en) 1991-05-21
DE3779500D1 (de) 1992-07-09
JP2572768B2 (ja) 1997-01-16
KR880000092A (ko) 1988-03-23
GR880300058T1 (en) 1988-10-18
EP0252290B1 (en) 1992-06-03
CA1303509C (en) 1992-06-16
AU605154B2 (en) 1991-01-10
AU7405387A (en) 1987-12-17
ES2042520T3 (es) 1993-12-16
PT85055A (pt) 1988-07-01
HUT43952A (en) 1988-01-28
KR950002150B1 (ko) 1995-03-14
US4826875A (en) 1989-05-02
EP0252290A3 (en) 1990-01-24

Similar Documents

Publication Publication Date Title
KR890001533A (ko) 레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
DE69430132D1 (de) Pernasale zusammensetzung und diese enthaltende pernasale zubereitung
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
KR970025615A (ko) 암 전이 억제제
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
KR910700045A (ko) Hiv 감염 관련 질병의 치료
ATE194987T1 (de) Substituierte dibenzoxazepinverbindungen, pharmazeutische zusammensetzungen und anwendungsmethoden
DK1201246T3 (da) Anvendelse af trombopoietin som et medikament til behandling og forebyggelse af trombocytopeni
KR910018020A (ko) 프라바스타틴과 피브르산 유도체의 혼합제. 및 이 혼합제를 사용한 이상지혈증 치료 방법
CO5160272A1 (es) Combinacion de cerivastatina y fibratos
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
KR890004705A (ko) 항바이러스성 제제
KR920702225A (ko) 약학 조성물
KR890701526A (ko) 각화증 치료제
ES2059348T3 (es) Composicion farmaceutica para el tratamiento de cataratas.
KR890007728A (ko) 진통제 제조방법
AR012972A1 (es) Forma farmaceutica para la administracion de paclitaxel, proceso para la preparacion de una composicion de paclitaxel lista para usar y uso de estacomposicion
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
KR960003717A (ko) 항암제에 의해 유발되는 말초신경병의 예방에 유용한 의약의 제조를 위한 엘리프로딜 및 그 거울상이성질체의 이용
KR950700063A (ko) 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)
KR950701216A (ko) 레마세미드의 파킨슨병 치료 용도(use of remacemide for the treatment of parkinson's disease)
KR880000094A (ko) 위염치료제
KR930017579A (ko) 신경 보호제

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090311

Year of fee payment: 15

EXPY Expiration of term